Co-developed accredited symposia

Multidisciplinary care of diabetic macular edema

Friday, February 27, 2015
0910-1010
PRINT POSTCARD

SCIENTIFIC PLANNING COMMITTEE

Dr. Geoff Williams, Chair
Dr. Matt Tennant
Dr. David Maberley
Dr. Amin Kherani, COS representative

SCHEDULE

0910	Welcome and introductions Geoff Williams
0920	DME trials David Maberley
0930	Diabetes 101 Alice Y.Y. Cheng
0940	DME – Bridging the gaps Peter J. Lin
0950	Panel discussion – Ask the ophthalmologist /endocrinologist / family doctor

Light snacks and refreshments will be served.

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

• Understand the most up-to-date clinical trial data for anti-VEGF use in the treatment of DME
• Describe the multifactorial approach to diabetes management as outlined in the Canadian Diabetes Association 2013 clinical practice guidelines
• Identify the gaps in care for patients with DME and create tools to help bridge these gaps
• Engage multiple stakeholders to improve the diagnosis and treatment of DME
• Better leverage the key roles played by family physicians, endocrinologists and ophthalmologists in the management of DME

ACCREDITATION STATEMENT This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 1 Section 1 credits. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at Earning credit for participation in international activities.

Physicians should only claim credits commensurate with the extent of their participation in the activity.

This symposium was co-developed with Alcon and was planned to achieve scientific integrity, objectivity and balance. The use of the partner logo is ethically permissible.

Management of macular holes 2015

Saturday, February 28, 2015
0910-1010
PRINT POSTCARD

SCIENTIFIC PLANNING COMMITTEE

Dr. David Chow, Co-chair
Dr. Michael Kapusta, Co-chair
Dr. Brad Hinz, COS representative

SCHEDULE
0910	Macular holes: Review of recent literature Netan Choudhry
0925	OCT reading: Identifying and measuring macular holes Allen Ho
0930	Panel discussion based on macular hole management Moderators: David Chow and Michael Kapusta
Light snacks and refreshments will be served.

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

• Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies
• Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions
• Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
• Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
• Optimize the management of macular holes in difficult-to-treat patients

ACCREDITATION STATEMENT This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 1 Section 1 credits. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at Earning credit for participation in international activities.

Physicians should only claim credits commensurate with the extent of their participation in the activity.

This symposium was co-developed with Alcon and was planned to achieve scientific integrity, objectivity and balance. The use of the partner logo is ethically permissible.